Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has accepted the filing ...
-- Curium's Investigational New Drug (IND) application for 177Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate cancer (mCRPC), has been accepted by the ...
Capital Brief on MSN
Telix Pharmaceuticals secures China approval for prostate cancer imaging filing
The news: Biotech company Telix Pharmaceuticals has received clearance from the Chinese National Medical Products ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback